{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:46:03Z","timestamp":1789058763270,"version":"build-2803163510"},"reference-count":35,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,9,10]]},"DOI":"10.1253\/circrep.cr-25-0077","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:09:18Z","timestamp":1752530958000},"page":"817-825","source":"Crossref","is-referenced-by-count":2,"title":["Differences in P2Y&lt;sub&gt;12&lt;\/sub&gt; Reaction Units Between Prasugrel and Clopidogrel by Ischemic Cerebrovascular Disease Subtypes\u3000\u2015 Subanalysis From ACUTE-PRAS \u2015"],"prefix":"10.1253","volume":"7","author":[{"given":"Shigeru","family":"Fujimoto","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Neurology, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Iguchi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamagami","sequence":"additional","affiliation":[{"name":"Department of Stroke Neurology, NHO Osaka National Hospital"},{"name":"Division of Stroke Prevention and Treatment, Institute of Medicine, University of Tsukuba"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Koga","sequence":"additional","affiliation":[{"name":"Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Itabashi","sequence":"additional","affiliation":[{"name":"Stroke Center, Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yakushiji","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kansai Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kowata","sequence":"additional","affiliation":[{"name":"Institute of Brain and Blood Vessels, Mihara Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Kimura","sequence":"additional","affiliation":[{"name":"Iwate Prefectural Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Terasawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Brain Attack Center Ota Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Shonan Kamakura General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Oki","sequence":"additional","affiliation":[{"name":"Tokyo Saiseikai Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Masuo","sequence":"additional","affiliation":[{"name":"Yokohama Municipal Citizen\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"National Hospital Organization Kagoshima Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Arakawa","sequence":"additional","affiliation":[{"name":"Steel Memorial Yawata Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Ueda","sequence":"additional","affiliation":[{"name":"St. Marianna University Toyoko Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryota","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Neurology, Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Data Intelligence Department, Daiichi Sankyo Co., Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Abe","sequence":"additional","affiliation":[{"name":"Primary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Kato","sequence":"additional","affiliation":[{"name":"Primary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taketoshi","family":"Furugori","sequence":"additional","affiliation":[{"name":"Primary Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Neurology, Graduate School of Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ACUTE-PRAS Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Capodanno D, Alberts M, Angiolillo DJ. Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. <i>Nat Rev Cardiol<\/i> 2016; 13: 609\u2013622.","DOI":"10.1038\/nrcardio.2016.111"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Gupta A, Baradaran H, Schweitzer AD, Kamel H, Pandya A, Delgado D, et al. Carotid plaque MRI and stroke risk: A systematic review and meta-analysis. <i>Stroke<\/i> 2013; 44: 3071\u20133077.","DOI":"10.1161\/STROKEAHA.113.002551"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Kuriakose D, Xiao Z. Pathophysiology and treatment of stroke: Present status and future perspectives. <i>Int J Mol Sci<\/i> 2020; 21: 7609.","DOI":"10.3390\/ijms21207609"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Edlow JA. Managing patients with transient ischemic attack. <i>Ann Emerg Med<\/i> 2018; 71: 409\u2013415.","DOI":"10.1016\/j.annemergmed.2017.06.026"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cole JW. Large artery atherosclerotic occlusive disease. <i>Continuum (Minneap Minn)<\/i> 2017; 23: 133\u2013157.","DOI":"10.1212\/CON.0000000000000436"},{"key":"6","unstructured":"6. Committee for Stroke Guideline 2021, The Japan Stroke Society. The Japan Stroke Society Guideline 2021 for the Treatment of Stroke [revised version 2023]. Kyowa Kikaku Ltd; 2023 [in Japanese]."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Prasad K, Siemieniuk R, Hao Q, Guyatt G, O\u2019Donnell M, Lytvyn L, et al. Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: A clinical practice guideline. <i>BMJ<\/i> 2018; 363: k5130.","DOI":"10.1136\/bmj.k5130"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Miyamoto S, Ogasawara K, Kuroda S, Itabashi R, Toyoda K, Itoh Y, et al. Japan Stroke Society Guideline 2021 for the Treatment of Stroke. <i>Int J Stroke<\/i> 2022; 17: 1039\u20131049.","DOI":"10.1177\/17474930221090347"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Han Y, Lv HH, Liu X, Dong Q, Yang XL, Li SX, et al. Influence of genetic polymorphisms on clopidogrel response and clinical outcomes in patients with acute ischemic stroke CYP2C19 genotype on clopidogrel response. <i>CNS Neurosci Ther<\/i> 2015; 21: 692\u2013697.","DOI":"10.1111\/cns.12426"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Mirabbasi SA, Khalighi K, Wu Y, Walker S, Khalighi B, Fan W, et al. CYP2C19 genetic variation and individualized clopidogrel prescription in a cardiology clinic. <i>J Community Hosp Intern Med Perspect<\/i> 2017; 7: 151\u2013156.","DOI":"10.1080\/20009666.2017.1347475"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. <i>JAMA<\/i> 2016; 316: 70\u201378.","DOI":"10.1001\/jama.2016.8662"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sawayama Y, Tomita Y, Kohyama S, Higo Y, Kodama K, Asada K, et al. Clopidogrel use in CYP2C19 loss-of-function carriers with high bleeding risk after percutaneous coronary intervention. <i>Circ J<\/i> 2023; 87: 755\u2013763.","DOI":"10.1253\/circj.CJ-22-0826"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Isshiki T, Kimura T, Ogawa H, Yokoi H, Nanto S, Takayama M, et al. Prasugrel, a third-generation P2Y<sub>12<\/sub> receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention. <i>Circ J<\/i> 2014; 78: 2926\u20132934.","DOI":"10.1253\/circj.CJ-14-0266"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kuno T, Miyamoto Y, Akita K, Shoji S, Numasawa Y, Ueda I, et al. Low-dose prasugrel vs. standard-dose clopidogrel for patients undergoing percutaneous coronary intervention. <i>Circ J<\/i> 2024; 88: 1745\u20131753.","DOI":"10.1253\/circj.CJ-24-0173"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Nakagawa Y, Kadota K, Nakao K, Shite J, Yokoi H, Kozuma K, et al. Early P2Y12 inhibitor single antiplatelet therapy for high-bleeding risk patients after stenting: PENDULUM Mono 24-month analysis. <i>Circ J<\/i> 2022; 86: 1352\u20131361.","DOI":"10.1253\/circj.CJ-21-1004"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, Kozuma K, et al. Clinical outcomes after percutaneous coronary intervention in east Asian patients: 30-month results of the PENDULUM Registry. <i>Circ J<\/i> 2022; 86: 1339\u20131349.","DOI":"10.1253\/circj.CJ-21-0991"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Iijima R, Kadota K, Nakao K, Nakagawa Y, Shite J, Yokoi H, et al. Ischemic and bleeding events in PENDULUM patients with high bleeding risk and high platelet reactivity. <i>Circ J<\/i> 2022; 86: 763\u2013771.","DOI":"10.1253\/circj.CJ-21-0717"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nakao K, Kadota K, Nakagawa Y, Shite J, Yokoi H, Kozuma K, et al. Changes in antithrombotic therapy over time and durability of a prasugrel WOEST-like regimen for percutaneous coronary intervention patients with atrial fibrillation: Post hoc analysis of the PENDULUM Mono and PENDULUM Registries. <i>Circ Rep<\/i> 2022; 4: 194\u2013204.","DOI":"10.1253\/circrep.CR-22-0032"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Ogawa A, Toyoda K, Kitagawa K, Kitazono T, Nagao T, Yamagami H, et al. Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: A phase 3, randomised, non-inferiority trial (PRASTRO-I). <i>Lancet Neurol<\/i> 2019; 18: 238\u2013247.","DOI":"10.1016\/S1474-4422(18)30449-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kitagawa K, Toyoda K, Kitazono T, Nishikawa M, Nanto S, Ikeda Y, et al. Safety and efficacy of prasugrel in elderly\/low body weight Japanese patients with ischemic stroke: Randomized PRASTRO-II. <i>Cerebrovasc Dis<\/i> 2020; 49: 152\u2013159.","DOI":"10.1159\/000506825"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kitazono T, Kamouchi M, Matsumaru Y, Nakamura M, Umemura K, Matsuo H, et al. Efficacy and safety of prasugrel vs clopidogrel in thrombotic stroke patients with risk factors for ischemic stroke recurrence: A double-blind, phase III study (PRASTRO-III). <i>J Atheroscler Thromb<\/i> 2023; 30: 222\u2013236.","DOI":"10.5551\/jat.63473"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Fujimoto S, Iguchi Y, Yamagami H, Koga M, Itabashi R, Yakushiji Y, et al. P2Y<sub>12<\/sub> reaction units with prasugrel in acute large artery atherosclerosis and transient ischemic attack: An open-label randomized controlled study, ACUTE-PRAS.  <i>Circ J<\/i> 2025, doi:10.1253\/circj.CJ-24-0949.","DOI":"10.1253\/circj.CJ-24-0949"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. <i>Stroke<\/i> 1993; 24: 35\u201341.","DOI":"10.1161\/01.STR.24.1.35"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Brott T, Adams HP Jr, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: A clinical examination scale. <i>Stroke<\/i> 1989; 20: 864\u2013870.","DOI":"10.1161\/01.STR.20.7.864"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS, Bernstein AL, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. <i>Lancet<\/i> 2007; 369: 283\u2013292.","DOI":"10.1016\/S0140-6736(07)60150-0"},{"key":"26","unstructured":"26. Pharmaceuticals and Medical Devices Agency. Efient\u00ae tablets [in Japanese]. https:\/\/www.info.pmda.go.jp\/go\/pdf\/430574_3399009F1020_1_21 (accessed December 18, 2024)."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. <i>Circulation<\/i> 2009; 119: 2625\u20132632.","DOI":"10.1161\/CIRCULATIONAHA.107.696732"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. <i>Lancet<\/i> 2004; 364: 331\u2013337.","DOI":"10.1016\/S0140-6736(04)16721-4"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Uehara T, Minematsu K, Ohara T, Kimura K, Okada Y, Hasegawa Y, et al. Incidence, predictors, and etiology of subsequent ischemic stroke within one year after transient ischemic attack. <i>Int J Stroke<\/i> 2017; 12: 84\u201389.","DOI":"10.1177\/1747493016669884"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Sakakura K, Nakano M, Otsuka F, Ladich E, Kolodgie FD, Virmani R. Pathophysiology of atherosclerosis plaque progression. <i>Heart Lung Circ<\/i> 2013; 22: 399\u2013411.","DOI":"10.1016\/j.hlc.2013.03.001"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Wi\u015bniewski A, Sikora J, S\u0142awi\u0144ska A, Filipska K, Karczmarska-W\u00f3dzka A, Serafin Z, et al. High on-treatment platelet reactivity affects the extent of ischemic lesions in stroke patients due to large-vessel disease. <i>J Clin Med<\/i> 2020; 9: 251.","DOI":"10.3390\/jcm9010251"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: A subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. <i>Lancet Neurol<\/i> 2017; 16: 301\u2013310.","DOI":"10.1016\/S1474-4422(17)30038-8"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hamana T, Sawada T, Fujimoto W, Osue T, Tsukiyama Y, Uzu K, et al. Comparison of the 9-month intrastent condition and 30-month clinical outcomes after resolute zotarolimus-eluting stent implantation between standard-duration and 1-month dual antiplatelet therapy followed by prasugrel monotherapy. <i>Circ Rep<\/i> 2021; 3: 55\u201365.","DOI":"10.1253\/circrep.CR-20-0126"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Umemura K, Iwaki T. The pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy Japanese volunteers. <i>Clin Pharmacol Drug Dev<\/i> 2016; 5: 480\u2013487.","DOI":"10.1002\/cpdd.259"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Li YG, Ni L, Brandt JT, Small DS, Payne CD, Ernest CS 2nd, et al. Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects. <i>Platelets<\/i> 2009; 20: 316\u2013327.","DOI":"10.1080\/09537100903046317"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/9\/7_CR-25-0077\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T03:49:38Z","timestamp":1757735378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/9\/7_CR-25-0077\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0077","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]},"article-number":"CR-25-0077"}}